FIELD: biotechnology.
SUBSTANCE: following is described: a group of inventions including a conjugate of a binding agent and a medicinal product for treating a subject who has or is suspected of having a neoplastic disease mesenchymal-epithelial transition factor (cMET)-expressing cancer or cMET-expressing cancer (variants). In one embodiment, the conjugate comprises a binding agent and a payload, wherein the binding agent comprises a heavy chain variable region comprising an amino acid sequence selected from the following SEQ ID NO: 105, 106, 107 and 108, and a light chain variable region containing an amino acid sequence selected from the following SEQ ID NO: 46, 47, 48 and 49.
EFFECT: invention expands the range of agents for the treatment of cMET-expressing cancer.
16 cl, 33 dwg, 12 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MONOCLONAL BINDING AGENTS, THEIR DRUG CONJUGATES AND THEIR APPLICATIONS | 2017 |
|
RU2744914C2 |
| ADVANCED SERUM ALBUMIN BINDING AGENTS | 2018 |
|
RU2797270C2 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| C3 BINDING AGENTS AND METHODS OF THEIR USE | 2019 |
|
RU2802307C2 |
| BISPECIFIC ANTIBODIES BINDING TO TFR | 2019 |
|
RU2810756C2 |
| HPV-SPECIFIC BINDING MOLECULES | 2018 |
|
RU2804664C2 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| BISPECIFIC ANTIBODIES SPECIFIC RELATIVELY TO COSTIMULATORY TNF-RECEPTOR | 2016 |
|
RU2761115C1 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
